ESMO Preceptorship Targeted Therapy for Gastric Cancer
|
|
- Silvia Carpenter
- 5 years ago
- Views:
Transcription
1 ESMO Preceptorship Targeted Therapy for Gastric Cancer Professor Dr. Florian Lordick Professor of Oncology Director University Cancer Center Leipzig (UCCL)
2 Disclosure Florian Lordick declares honoraria for advisory role, membership in data safety board or lectures within the last three years for Amgen, Astellas, Astra Zeneca, Biontech, BMS, Ganymed, Elsevier, Excerpta Medica, MSD, Roche, Servier, and Taiho. He receives research support from BMS 2
3 Systemic Treatment Options in GC Chemotherapy Molecular Targeted therapy Antiangiogenic therapy Immuno therapy 3
4 Targeted Therapy in GC Not a Success Story Compound Mechanism of action Treatment setting Reference Cetuximab Anti-EGFR mab 1 st -line metastatic Lordick et al Panitumumab Anti-EGFR mab 1 st -line metastatic Waddell et al Gefitinib Anti-EGFR TKI 2 nd -line metastatic Petty et al Trastuzumab Anti-HER2 mab 2 nd -line metastatic Makiyama et al Pertuzumab Anti-HER2 mab 1 st -line metastatic Tabernero et al Lapatinib Anti-EGFR/HER2 TKI 2 nd -line metastatic Satoh et al Rilotumumab Anti-HGF mab 1 st -line metastatic Catenacci et al Onartuzumab Anti-MET mab 1 st -line metastatic Shah et al Napabucasin Anti-STAT3 2 nd -line metastatic Shah et al Bevacizumab Anti-VEGF mab Perioperative Cunningham et al Bevacizumab Anti-VEGF mab 1 st -line metastatic Ohtsu et al Ramucirumab Anti-VEGFR-2 mab 1st-line metastatic Fuchs et al Olaparib PARP inhibitor 2 nd -line metastatic Bang et al Pembrolizumab PD-1-directed mab 2 nd -line metastatic Shitara et al. Lancet
5 Potential Molecular Targets in Gastric Cancer Deng N, et al. Gut 2012;61:
6 Potential Molecular Targets in Gastric Cancer Anti-EGFR negative phase-3: EXPAND, REAL3 Lordick et al. Lancet Oncol 2013 Waddell et al. Lancet Oncol 2013 Anti-MET negative phase-3: MetMab, RiloMet Shah et al. ASCO 2015 Cunningham et al. ASCO 2015 anti-fgfr preliminary phase-2: Shine Bang et al. ASCO 2015 KRAS non druggable (?) HER2 positive phase-3: ToGA Bang et al. Lancet 2010 Genomic DNA were extracted from flash-frozen tissues or cell pellets using a Qiagen genomic DNA extraction kit (Qiagen, Hilden, Germany), and profiled on Affymetrix SNP 6.0 arrays (Affymetrix, Santa Clara, California, USA) Deng N, et al. Gut 2012;61:
7 The EGFR Story mixed, 3+ intestinal, 0-3+ Expression bei Magenkarzinomen (Immunhistochemie) diffuse, 2+ diffuse, 1+ Gamboa et al. Mod Pathol 2004;17:
8 The EGFR Story n Response (%) mttp (Mon) FUFOX + Cetuximab Lordick F, et al. BJC % 95% CI, 50 79% 7,6 95% CI, Lordick F, et al. Br J Canc 2010; 102:
9 EXPAND Study R A N D O M Cisplatin 80mg/m 2 d1 Capecitabine 1000mg/m 2 2 x / day.; d1-14 q3w Until radiographic progression or toxicity-related end of treatment Primary endpoint: Progression-free survival (PFS) Cisplatin 80mg/m 2 d1 Capecitabine 1000mg/m 2 2 x tgl.; d1-14 q3w Cetuximab 400mg/m 2 loading dose, then 250mg/m 2 / week Lordick et al., Lancet Oncol. 2013; 14:
10 EXPAND Study Lordick et al., Lancet Oncol. 2013; 14:
11 Survival (%) Pre-EXPAND Study 100 EGFR FISH >4.0 Log-rank P= n=8 40 EGFR gene amplification: EGFR: 8.20 signals per nucleus EGFR/CEP7 ratio: 1.36 EGFR (red), chromosome 7 (green) 20 0 EGFR FISH < Overall survival time (days) n=28 Luber B, Lordick F. BMC Cancer 2011;11:509 11
12 EXPAND Study Lordick et al., Lancet Oncol 2012; 13:
13 What Can We Learn from the EGFR Lesson? A good study hypothesis is important: preclinical evidence Do not trust in overoptimistic phase II data Do correlative research and explore biomarkers! For rare subtypes of cancer - you need a strong network! 14
14 HER2-directed Therapy: ToGA Anti-HER2 Trastuzumab prolongs survival in stage IV gastric cancer Lordick F, Janjigian YY. Nat Rev Clin Oncol 2016 Survival advantage with trastuzumab in HER2 + gastric cancer CI, confidence interval; HER2, human epidermal growth factor receptor 2; HR, hazard ratio. Bang Y, Lordick F. et al. Lancet 2010;376:
15 Gastric Cancer Therapy in Stage IV HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridisation. Lordick F, Janjigian YY. Nat Rev Clin Oncol Jun;13(6):348-60
16 HER2 Combined Therapy: Pertuzumab - Trastuzumab The mechanism of action of pertuzumab and trastuzumab. Trastuzumab binds to the ECD IV of the HER2 receptor, preventing the spontaneous formation of homodimers (HER2 HER2) and ligand-independent heterodimers (HER2 HER3 and also HER2 HER1 and HER2 HER4). Pertuzumab binds to the dimerization domain of the HER2 receptor (ECD II), preventing the formation of ligand-induced HER2 heterodimers. Metzger-Filho O, et al. Clin Cancer Res 2013; 19:
17 Pertuzumab Trastuzumab JACOB Study Arm A (n=388) Arm B (n=392) HR (95%CI) mpfs, months (0.62, 0.86) Response rate (%) Difference 8.4 (0.9, 15.9) Tabernero J et al. Lancet Oncol Sep 11. [Epub ahead of print 18
18 Target Expression in Gastric Cancer Heterogenous / focal HER-2 expression in gastric cancer Signet ring type Intestinal (gland forming) type High Amplification No Amplification Lordick F, Janjigian YY. Nat Rev Clin Oncol Jun;13(6):
19 HER2-Testing Central and Local Lordick et al. AACR, Chicago, 2018 abstract
20 HER2-Testing Central and Local Deviation rate 23% Lordick et al. AACR, Chicago, 2018 abstract 21
21 HER2-Testing Central and Local Lordick et al. AACR, Chicago, 2018 abstract 22
22 Gastric Cancer Therapy in Stage IV HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridisation. Lordick F, Janjigian YY. Nat Rev Clin Oncol Jun;13(6):348-60
23 2nd-line HER2-targeted treatment? Makiyama et al. ASCO 2018; #
24 2nd-line HER2-targeted treatment? Makiyama et al. ASCO 2018; #
25 2nd-line HER2-targeted treatment? PIK3CA WT PIK3CA E454K Mutation Janjigian Y et al.. Cancer Discovery 2018 Jan;8(1):
26 Tumor Heterogeneity and Evolution Tumor Heterogeneity Biological Evolution Treatment Resistance 27
27 Tumor Heterogeneity Pectasides et al. Cancer Discovery 2017; 8:
28 Tumor Heterogeneity in GC Pectasides et al. Cancer Discovery 2017; 8:
29 Tumor Heterogeneity in GC Pectasides et al. Cancer Discovery 2017; 8:
30 Tumor Heterogeneity and Evolution Aparicio & Caldas et al. N Engl J Med 2013; 368:
31 Tumor Size Tumor Heterogeneity and Evolution Time Baseline Sampling Relapse Progression Resection, adjuvant Drug A Drug B (Metastases) 32
32 Liquid Biopsy Diaz et al. J Clin Oncol 2014; 32:
33 Anti-Angiogenic Approach Dr. Judah Folkman, Boston Folkman s Hypothesis Folkman J, et al. N Engl J Med 1971;285:1182 6
34 Anti-Angiogenic Approach Clarke JM et al. Expert Opin Biol Ther 2013; 13:
35 Ramucirumab 2nd-line Mono (REGARD) RAM + BSC Placebo + BSC HR P-value Disease Control 49% 23% P< PFS (med, Mon) OS (med, Mon) HR 0.48 p < HR 0.78 p = FU, fluorouracil; CI, confidence interval; EGJ, oesophageal junction; HR, hazard ratio. Fuchs CS, et al. Lancet 2014;383:31 9
36 Ramucirumab 2nd-line Mono Median OS (months) by Study Arm REGARD: Ramucirumab vs PBO (BSC) (n=355) Ramucirumab vs BSC (n=355) UK: COUGAR-02: Docetaxel vs BSC 1 Docetaxel vs ASC (n=131) (n=131) CTX [Docetaxel or Irinotecan] vs BSC (n=202) Korea: CTX [Docetaxel or Irinotecan] vs BSC 2 (n=202) German: Irinotecan vs BSC 3 Irinotecan vs BSC (n=40) (n=40) Active Treatment BSC 1. Ford et al. Lancet Oncol Jan;15(1): Kang et al. J Clin Oncol 2012;30: Thuss-Patience et al. EUR J CANCER 2011;47:
37 Ramucirumab 2nd-line Combined (RAINBOW) RAM + Paclitaxel Placebo + Paclitaxel HR P-value Response Rate 28% 16% p = PFS (med, Mon) 6 months (%) % % HR p < OS (med, Mon) 6 months % % HR p = Wilke et al., Lancet Oncol 2014 Oct;15(11):
38 Ramucirumab 2nd-line Quality of Life (RAINBOW) Dyspnoea Diarrhoea Favours RAM+PTX Favours PBO+PTX CI, confidence interval; HR, hazard ratio; PBO, placebo; PTX, paclitaxel; RAM, ramucirumab Al-Batran SE, et al. Ann Oncol Apr;27(4):673-9
39 Is Ramucirumab Effective in HER2 Positive Cancers? Post-hoc analysis from Regard Fuchs C et al Brit J Cancer 2016 Oct 11;115(8):
40 Ramucirumab in the Elderly Population? REGARD STUDY RAINBOW STUDY Fuchs C et al Brit J Cancer 2016 Oct 11;115(8): Wilke et al., Lancet Oncol 2014 Oct;15(11):
41 Ramucirumab in the Peritoneal Carcinosis? REGARD STUDY RAINBOW STUDY Fuchs C et al Brit J Cancer 2016 Oct 11;115(8): Wilke et al., Lancet Oncol 2014 Oct;15(11):
42 Anti-Angiogenic Treatment in Early Gastric Cancer or 1st-Line Metastatic GC: not effective Study Setting Drug Control (C) Reference STO-3 Peri-operative BEV+C ECX 1 AVAGAST AVATAR NCT RAINFALL RAINSTORM 1st-line metastatic 1st-line metastatic 1st-line metastatic 1st-line metastatic 1st-line metastatic BEV+C CF 2 BEV+C XP 3 RAM+C FOLFOX 4 RAM+C CF 5 RAM+C SOX 9 1. Bev: Bevacizumab C: Control CF: Cisplati, 5-Fluorouracil ECX: Epirubicin, Cisplatin, Capecitabin FOLFOX: Folinic Acid, 5-Fluorozracil, Oxaliplatin SOX: S-1, Oxaliplatin XP: Capecitabine, Cisplatin Cunningham D et al. Lancet Oncol 2017; 18: Ohtsu A et al. J Clin Oncol 2011; 29: Shen L et al. Gastric Cancer 2015; 18: Yoon HH et al. Ann Oncol Dec;27(12): Fuchs C et al. ASCO-GI 2018; abstract # Muro K. Et al. ASCO 2018; abstract #4038
43 Anti-Angiogenic Treatment Among Treatment Lines Stomach Cancer Colorectal Cancer Disease setting Localized : Impact in OS : Impact in PFS : No Impact in OS/DFS/PFS Perioperative or Adjuvant Locally advanced Metastatic and Mostly Palliative 1 st 2 nd Advanced 3 rd - Yoon HH, ASCO-GI 2015, substantially modified by Muro K
44 2nd-line Treatment Algorithm for Gastric Cancer ECOG, Eastern Cooperative Oncology Group; PS, performance status. Lordick F, Janjigian YY. Nat Rev Clin Oncol Jun;13(6):348-60
45 Summary Gastric cancer is a heterogenous disease, which compromises - to a certain extent targeted treatment Trastuzumab plus chemo-doublet improves survival in firstline metastatic gastric cancer Other receptor tyrosine kinase directed treatments have failed thus far Ramucirumab alone and - even more - ramucirumab plus paclitaxel improves survival in 2nd-line gastric cancer Universitätsklinikum Leipzig AöR (2009): Thema, Autor 46
46 8 11 May 2019, Prague
47 Back-Up Slides 48
48 Perioperative anti-her2 Therapy TRIGGER study SP HER2 + GC, Bulky N SP / Tmab Surgery S-1 Surgery S-1 Sample size: 130 pts. Primary endpoint: Overall survival Secondary endpoint: Progression-free survival, response rate, completion of protocol treatment, adverse event Legend: SP, S-1 plus Cisplatin; Tmab, Trastuzumab 49
49 Perioperative INNOVATION study HER2-positive mgc or GEJ adenocarcinoma (N = 220) Centrally confirmed Stages IB-III R 1:2:2 XC or FLOT 3 / 4 cycles (N = 44) Chemo + T 3 cycles (N = 88) Chemo + TP 3 cycles (N = 88) Surgery XC or FLOT 3 / 4 cycles Chemo + T 3 cycles Chemo + TP 3 cycles T for up to 1 year TP for up to 1 year T: Trastuzumab; P: Pertuzumab Primary endpoint: histopathological near complete response (<10% viable tumour cells) after neoadjuvant therapy Stratification: histological subtype (intestinal/non-intestinal); Korea versus Europe; stage II versus III; node positive versus node negative 50
BIOLOGICAL TARGETED AGENTS
BIOLOGICAL TARGETED AGENTS (INCLUDING HER2, EGFR, ANGIOGENESIS) Dr Elizabeth Smyth Royal Marsden Hospital ESMO GI Cancer Preceptorship Singapore 2017 DISCLOSURES Honoraria for advisory role Five Prime
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationResectable locally advanced oesophagogastric cancer
Resectable locally advanced oesophagogastric cancer Clinical Case Discussion Florian Lordick University Cancer Center Leipzig University Clinic Leipzig Leipzig, Germany esmo.org DISCLOSURES Honoraria for
More informationUpdates and best practices in the management of gastric cancer
Updates and best practices in the management of gastric cancer Olatunji B. Alese, MD Gastrointestinal Oncology, Winship Cancer Institute of Emory University July 28, 2017 1 Incidence 3rd leading cause
More informationSystemic treatment in early and advanced gastric cancer
Systemic treatment in early and advanced gastric cancer Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer n Surgical resection n Pathology assessment and estimation
More information(Neo-) adjuvant Treatment of Gastric Cancer. - The European View
(Neo-) adjuvant Treatment of Gastric Cancer - The European View Florian Lordick, MD Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) University of Leipzig, Germany My Conflict
More informationNew experimental targets for gastric cancer Andrés Cervantes
New experimental targets for gastric cancer Andrés Cervantes Professor of Medicine Outline Acquired capabilities of Cancer IGFR pathway PI3K-AKT-m-TOR pathway MET pathway FGFR pathway Check point inhibitors
More informationAdvances in gastric cancer: Biology and Treatment for advanced disease
Advances in gastric cancer: Biology and Treatment for advanced disease Andrés Cervantes Professor of Medicine Outline Molecular classification Pathology Classification after gene expression The Cancer
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationCurrent standards of care in gastric cancer
Current standards of care in gastric cancer Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Outline Resectable gastric cancer: the role of neoadjuvant and adjuvant
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationNOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO
NOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO ONCOLOGIA MEDICA 1 FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI MILANO PROGRESS AGAINST METASTATIC GC OS in first-line palliative setting Little progress
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationCurrent Standard of Care of Gastric Cancer:
Current Standard of Care of Gastric Cancer: Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation of risk Treatment
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Anna Dorothea Wagner, PD & MER Department of Oncology University of Lausanne Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Structure 1. Background and overview 2. Adjuvant chemotherapy:
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationManagement of advanced Gastric Cancer in the era of targeted therapy
Management of advanced Gastric Cancer in the era of targeted therapy Osman M.Mansour Prof. Medical Oncology, NCI, Cairo University BGO: 28-3 October 215 Gastric Cancer: A Significant Problem in Some Countries
More informationPerioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran
Perioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran Institute of Clinical Cancer Research Krankenhaus Nordwest UCT - University Cancer Center
More informationCurrent Standard of Care of Gastro- Esophageal Cancer
Current Standard of Care of Gastro- Esophageal Cancer Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation of risk
More informationCHEMOTHERAPY FOR METASTATIC GASTRIC CANCER
CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER Dr Elizabeth Smyth Royal Marsden, UK ESMO Gastric Cancer Preceptorship Valencia 2017 IMPORTANT CONSIDERATIONS WHEN TREATING ADVANCED GASTRIC CANCER Short OS Pain
More informationGastric: 16% 18% 27% Esophageal: 5% 10% 19%
2.5% of all cancers Median age 68 years Decline in gastric cancer incidence Increase in esophageal, GEJ, cardia adenocarcinoma OS improvement, 1975-77, 1984-86, 1999-2006 Gastric: 16% 18% 27% Esophageal:
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationGetting to the Bottom of Treatment: An Update in the Management of Esophagogastric Cancers
Getting to the Bottom of Treatment: An Update in the Management of Esophagogastric Cancers Disclosures None Cindy L. O Bryant, PharmD, BCOP, FCCP, FHOPA Professor, University of Colorado Skaggs School
More informationChemotherapy for metastatic gastric cancer
ESMO Asia GI Preceptorship 2018 Chemotherapy for metastatic gastric cancer Sun Young Rha, MD, PhD Yonsei Cancer Center, Institute for Cancer Research, Yonsei University College of Medicine Disclosures
More informationChemotherapy for metastatic gastric cancer
ESMO Asia GI Preceptorship 2017 Sun Young Rha, MD, PhD Yonsei Cancer Center, Institute for Cancer Research, Yonsei University College of Medicine Chemotherapy for metastatic gastric cancer Disclosures
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationUpdated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre)
Metastatic Esophagogastric Cancer Summary Updated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University
More informationPCPA Advanced Trainee Program Upper GI Cancers. Dr N Singhal Medical Oncologist Royal Adelaide Hospital
Upper GI Cancers Dr N Singhal Medical Oncologist Royal Adelaide Hospital Localised disease PCPA Advanced Trainee Program 2018 Submucosal PCPA Advanced Trainee Program 2018 Work up EUS- 90% sensitivity
More informationTargeted Therapies in Gastric Cancer : Where Do We Stand Today. Yoon-Koo Kang Asan Medical Center, University of Ulsan Seoul, Korea
Targeted Therapies in Gastric Cancer : Where Do We Stand Today Yoon-Koo Kang Asan Medical Center, University of Ulsan Seoul, Korea Chemotherapy is the standard of care in advanced gastric cancer Median
More informationWhere Are We with Check-Point Inhibitors in Gastric Cancer?
21 June 2018, Barcelona Session VII: Metastatic Gastric Cancer Where Are We with Check-Point Inhibitors in Gastric Cancer? Kei Muro, MD. kmuro@aichi-cc.jp Department of Clinical Oncology Aichi Cancer Center
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationBodoky G, Gil-Delgado M, Cascinu S, Lipatov ON, Cunningham D, Van Cutsem E, Muro K, Chandrawansa K, Liepa AM, Carlesi R, Ohtsu A, Wilke H
Characterizing Tumor Responses From RAINBOW, a Randomized Phase III Trial of Ramucirumab (RAM) Plus Paclitaxel (PAC) vs Placebo (PBO) Plus PAC in Patients (pts) With Previously Treated Advanced Gastric
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Priv. Doz. Dr. Dr. med. T.O. Götze Institute of Clinical Cancer Research Director: Prof. Dr. S.-E. Al- Batran University Cancer
More informationAntiangiogenic therapy in GI cancer: current status and future directions
Riccardo Giampieri, MD, PhD Università Politecnica delle Marche Ospedali Riuniti diancona Antiangiogenic therapy in GI cancer: current status and future directions Before starting Summary - Antiangiogenesis
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationEsophageal and GEJ Cancers. Case Presentations
Esophageal and GEJ Cancers Case Presentations Locally Advanced GEJ Cancer (Case 1) A 55 year old man with longstanding GERD presents with increasing solid food dysphagia. EGD reveals a 3 cm mass in the
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationGeneral Overview of ASCO GI Alberto Zaniboni Oncologia Medica Fondazione Poliambulanza - Brescia
General Overview of ASCO GI 2018 Alberto Zaniboni Oncologia Medica Fondazione Poliambulanza - Brescia Le mie disclosures Research grants: Roche, Novartis, Pfizer, Astra Zeneca, Janssen, Boheringer Advisory
More informationAIOM POST-ASCO GI 2018 HIGHLIGHTS ESOPHAGUS AND STOMACH CANCER
Mario Scartozzi Oncologia Medica Università degli Studi Azienda Ospedaliero-Universitaria Cagliari AIOM POST-ASCO GI 2018 HIGHLIGHTS ESOPHAGUS AND STOMACH CANCER (WE CAN T GET NO) SATISFACTION LET THEM
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationPersonalised Medicine
Personalised Medicine Panacea or Pandora s box? Dr Tom Lillie Oncology Therapeutic Area Head Amgen October 2012 Amgen is the world s leading biotechnology company employs more than 17,000 staff in 39 countries
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationMedicina Personalizada de Precisión en el Abordaje del Cáncer Gástrico. Dra Desamparados Roda Pérez Hospital Clínico de Valencia Incliva, CIBERONC
Medicina Personalizada de Precisión en el Abordaje del Cáncer Gástrico Dra Desamparados Roda Pérez Hospital Clínico de Valencia Incliva, CIBERONC Gastric cancer Epidemiology Gastric cancer is an important
More informationMy name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York.
Welcome to this CME/CE-certified activity entitled, Integrating the Latest Advances Into Clinical Experience: Data and Expert Insights From the 2016 Meeting on Gastrointestinal Cancers in San Francisco.
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationTargeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example
Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example Dennis J Slamon, MD, PhD Professor of Medicine Chief, Division of Hematology/Oncology; Director of Clinical/Translational
More informationMolecular events in gastric cancer
Molecular events in gastric cancer Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria Pisana Istituto Toscano Tumori Pisa- Italy Disclosures No conflict of interest to disclose
More informationSystemic therapy for esophagogastric cancer: targeted therapies
Review Article on Esophagus Cancer Page 1 of 16 Systemic therapy for esophagogastric cancer: targeted therapies Tomas G. Lyons, Geoffrey Y. Ku Gastrointestinal Oncology Service, Department of Medicine,
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationTargeted therapy in gastroesophageal cancers: past, present and future
Gastroenterology Report, 3(4), 2015, 316 329 doi: 10.1093/gastro/gov052 Advance Access Publication Date: 27 October 2015 Review REVIEW Targeted therapy in gastroesophageal cancers: past, present and future
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationRationale for VEGFR-targeted Therapy in RCC
Rationale for VEGFR-targeted Therapy in RCC EIKCS, Budapest, May 2013 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca + + + Astellas
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015
pan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More informationPanitumumab: The KRAS Story. Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd
Panitumumab: The KRAS Story Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd Clinical Background: panitumumab in mcrc Panitumumab is a fully human IgG2 monoclonal antibody directed
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationConcept to Practice: New Advances in the Treatment of GI Cancers
Concept to Practice: New Advances in the Treatment of GI Cancers 2016 Community Oncology Alliance Conference Orlando, FL Thomas George, MD, FACP Director, GI Oncology Program Director, Experimental Therapeutics
More informationColon Cancer Molecular Target Agents
Colon Cancer Molecular Target Agents Ci Caio Max SR S. Rocha Lima, M.D. MD Professor of Medicine CDi CoDiretor Cl Colorectal tlheptobiliary, Pancreatic SDG, and Phase I Unit University of Miami & Silvester
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationESMO Asia 2016 Industry Satellite Symposium December 2016, Singapore. Advances in gastric cancer
ESMO Asia 2016 Industry Satellite Symposium 16 19 December 2016, Singapore Advances in gastric cancer Chair: Ian Chau With Mitsuru Sasako, Kei Muro and Yung-Jue Bang Saturday 17th December, 12:45-14:15
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationTumores esófago-gástricos, tiene algo que decir la inmunoterapia? Dr. Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla.
Tumores esófago-gástricos, tiene algo que decir la inmunoterapia? Dr. Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla. Santander Finantial disclosure Consultor: CELGENE Research fundings:
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationAdjuvant treatment for stage III colon cancer
ESMO Preceptorship Programme Rectal cancer Singapur November 2017 Adjuvant treatment for stage III colon cancer Andrés Cervantes Disclosures Consulting and advisory services, speaking or writing engagements,
More informationOverview on Gastric Cancer
Chapter 1 Targeted Therapy and Immunotherapy Daniel da Motta Girardi * Department of oncology, Hospital Sirio-Libanês, Brasília, Brazil. *Correspondense to: Daniel da Motta Girardi, Department of oncology,
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationCOMETS: COlorectal MEtastatic Two Sequences
COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed
More informationAddressing Tumor Molecular Heterogeneity using A Novel Clinical Trial Design - PANGEA
Addressing Tumor Molecular Heterogeneity using A Novel Clinical Trial Design - PANGEA Daniel Catenacci, MD Assistant Professor of Medicine Associate Director GI Oncology Program May 12, 2017 Addressing
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationUpper Gastrointestinal Cancers in the Elderly. Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore
Upper Gastrointestinal Cancers in the Elderly Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore Gastric Cancer --High Global Burden Global Cancer Deaths % of all cancer (2008)
More informationADVANCES IN COLON CANCER
ADVANCES IN COLON CANCER Peter T. Silberstein, M.D., FACP Professor, Creighton University Chief Hematology/Oncology UNIVERSAL SCREENING FOR LYNCH SYNDROME OF ALL PATIENTS WITH COLON CANCER ADOPTED BY CHI
More informationCetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationValidated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD
Validated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD U.O. Oncologia 2 Universitaria Azienda Ospedaliero-Universitaria Pisana Pisa, Italy Learning Objectives
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationContinuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience
Original Article Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience Humaid O. Al-Shamsi 1, Yazan Fahmawi 1, Ibrahim Dahbour 1,
More informationGastric cancer is the fourth
Section Editors: Christopher J. Campen and Beth Eaby-Sandy Ramucirumab: A New Therapy for Advanced Gastric Cancer ANDREA LANDGRAF OHOLENDT, PharmD, BCOP, and JENNIFER L. ZADLO, PharmD, BCOP From The University
More informationTargeted therapy of gastric cancer: current and prospective strategies*
Oncology and Translational Medicine DOI 10.1007/s10330-018-0263-3 April 2018, Vol. 4, No. 2, P41 P47 REVIEW ARTICLE Targeted therapy of gastric cancer: current and prospective strategies* Tingting Huang,
More informationTHE ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE V1.1
THE ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE V1.1 User instructions and ESMO-MCBS case studies Prepared by Elisabeth de Vries, Nathan Cherny and Nicola Latino DISCLURES Elisabeth de Vries does not hold
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationGastric and Colon Cancer. Dr. Andres Wiernik 2017
Gastric and Colon Cancer Dr. Andres Wiernik 2017 GASTRIC CANCER Gastric Cancer Classification Epidemiology General principles of Management 25% GE Junction Gastric Cancer 75% Gastric Cancer Epidemiology
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More information